Capecitabine

About

Therapy type: Chemotherapy

Therapy strategy: Thymidylate synthase inhibition

Mappings

NCI Thesaurus: Capecitabine (ncit:C1794)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Capecitabine
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Margetuximab
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Neratinib
Sensitivity (+) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
Sensitivity (+) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib
Sensitivity (+) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Zolbetuximab
Sensitivity (+) HER2-positive Esophagogastric Adenocarcinoma Capecitabine, Cisplatin, Trastuzumab
Sensitivity (+) ERBB2 amplification Esophagogastric Adenocarcinoma Capecitabine, Cisplatin, Trastuzumab
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib
Sensitivity (+) ERBB2 amplification Invasive Breast Carcinoma Capecitabine, Lapatinib
Sensitivity (+) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Zolbetuximab
Sensitivity (+) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Capecitabine
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib